FY2027 EPS Estimates for Genmab A/S Lowered by William Blair

Genmab A/S (NASDAQ:GMAB - Free Report) - William Blair dropped their FY2027 earnings estimates for Genmab A/S in a research note issued to investors on Friday, May 9th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $2.58 per share for the year, down from their prior estimate of $2.69. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%.

Other equities analysts have also issued research reports about the stock. BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Up 1.2%

Shares of NASDAQ:GMAB traded up $0.23 during trading on Monday, reaching $19.88. The stock had a trading volume of 836,564 shares, compared to its average volume of 1,112,041. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.06. The business has a fifty day moving average price of $19.74 and a 200-day moving average price of $20.75. The stock has a market cap of $12.75 billion, a P/E ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC boosted its stake in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Crossmark Global Holdings Inc. boosted its stake in shares of Genmab A/S by 8.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 41,622 shares of the company's stock valued at $868,000 after purchasing an additional 3,377 shares during the period. SG Americas Securities LLC boosted its stake in shares of Genmab A/S by 82.7% in the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company's stock valued at $551,000 after purchasing an additional 11,949 shares during the period. Blue Trust Inc. boosted its stake in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after purchasing an additional 1,442 shares during the period. Finally, R Squared Ltd purchased a new position in shares of Genmab A/S in the fourth quarter valued at $93,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.